Levomilnacipran
- Generic Name
- Levomilnacipran
- Brand Names
- Fetzima
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22N2O
- CAS Number
- 96847-54-0
- Unique Ingredient Identifier
- UGM0326TXX
- Background
Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake. Levomilnacipran is the more active 1S,2R-enantiomer in the racemate milnacipran. Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in hum...
- Indication
Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor indicated for the treatment of major depressive disorder (MDD) in adults.
- Associated Conditions
- Major Depressive Disorder (MDD)
- Associated Therapies
- -
Major Depressive Disorder Market to Register Immense Growth by 2034 Owing to a Robust Pipeline
New treatments like COMP360, Zuranolone, LY03005, REL-1017, Seltorexant, and ABV-1504 are expected to significantly transform the major depressive disorder (MDD) market. MDD affects 44 million diagnosed cases in the 7MM, with moderate cases being the most prevalent. Treatment approaches include pharmacological interventions, psychotherapy, and lifestyle changes. The market size for MDD is projected to grow from USD 7.1 billion in 2023, driven by disease awareness and new product launches.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath